Singular Genomics Systems, Inc. (OMIC)

USD 19.6

(-0.56%)

Market Cap (In USD)

49.23 Million

Revenue (In USD)

2.91 Million

Net Income (In USD)

-94.82 Million

Avg. Volume

91.09 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.34-23.41
PE
-
EPS
-
Beta Value
1.514
ISIN
US82933R1005
CUSIP
82933R100
CIK
1850906
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Mr. Andrew Spaventa
Employee Count
-
Website
https://singulargenomics.com
Ipo Date
2021-05-27
Details
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.